Pan-vascular diseases, one of the leading causes of death among Chinese residents, represent a systemic vascular syndrome characterized by atherosclerosis as a common pathological feature. This condition can lead to damage in multiple target organs, including the heart, brain, kidneys, retina, and peripheral vessels. Current prevention and control efforts face critical challenges. Western medicine's disciplinary specialization often leads to excessive focus on localized lesions, whereas Traditional Chinese Medicine's (TCM) holistic diagnostic and therapeutic system offers distinct advantages in systemic management. Evidence-based research confirms the efficacy of Chinese patent medicines in treating systemic vascular diseases, particularly those related to atherosclerosis. Currently, there is a lack of clinical guidelines based on evidence-based medicine for the prevention and treatment of pan-vascular diseases and their target organ damage using Chinese patent medicines, both domestically and internationally. This consensus was initiated by the China association for the Promotion of Traditional Chinese Medicine. Under the academic guidance of Academician GE Junbo and Academician CHEN Kejie, Experimental research center, China Academy of Chinese Medical Sciences led the formation of the Expert Group for the "Expert Consensus on the Use of Traditional Chinese Patent Medicines in the Prevention and Treatment of Pan-vascular Diseases and Their Target Organ Damage". This consensus was developed through a panel of renowned physicians, covering consensus development methodologies, TCM theoretical interpretations of pan-vascular diseases, evidence-based recommendations for TCM patent medicines in their prevention and treatment, and clinical application considerations. It aims to provide an optimized integrated Chinese and Western medicine solution for the comprehensive management of pan-vascular diseases, standardize the principles of TCM patent medicine use in preventing and treating pan-vascular diseases and target organ damage, and enhance the scientific rigor and standardization of clinical practice.

泛血管疾病作为中国居民的主要死因之一，是以动脉粥样硬化为共同病理特征的全身性血管综合征，可导致心、脑、肾、视网膜及外周血管等多系统靶器官损害。当前泛血管疾病防控面临关键挑战，西医学科细分易导致过度关注局部病变，而中医基于整体观的辨证论治体系，在系统性防控中具有显著优势。循证研究证实，中成药在全身血管性疾病（尤其是动脉粥样硬化相关疾病）中疗效确切。目前国内外尚缺乏基于循证医学证据的中成药防治泛血管疾病及其靶器官损害的临床指引，本共识由中国中医药研究促进会立项，在葛均波院士与陈可冀院士的学术指导下，由中国中医科学院医学实验中心牵头组建《中成药防治泛血管疾病及其靶器官损害的专家共识》专家组制订。本共识采用名医群体法制订，涵盖共识制订方法、泛血管疾病的中医理论诠释、防治泛血管疾病及其靶器官损害的中成药循证推荐方案及临床应用注意事项，旨在为泛血管疾病全程管理提供中西医协同优化解决方案，规范中成药防治泛血管疾病及其靶器官损害的用药原则，以提升临床实践的科学性和规范性。